fbpx

Year

2017
Lead candidate, light-activated AU-011, currently being investigated in Phase 1b/2 study to treat ocular melanoma, an orphan indication Funding to support ongoing clinical development, enabling buildout of company infrastructure and GMP manufacturing CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle...
Last Patient Last Visit (LPLV) completed in Phase II Study for the Treatment of Calcific Uraemic Arteriolopathy in End Stage Renal Disease Patients Palma, Spain and San Diego, USA, December 21, 2017 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, announced today that the Last Patient’s Last Visit (LPLV) occurred...
Approval granted several months ahead of the initial schedule Launch of HEMOBLAST™ Bellows in the United States expected over the summer in 2018 Saint-Priest, France, December 18, 2017 – Biom’Up, specialist in surgical hemostasis, announces today that it has received FDA marketing approval for HEMOBLASTTM Bellows, its flagship product, 7 months ahead of schedule. This pre-marketing...
Lund, Sweden, 08.00 CET, 13 December 2017 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces that it has achieved its aim of recruiting 136 patients into the CERTiFy (CERAMENT® Treatment of Fracture defects)...
BURLINGTON, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to transform infused therapies, advance patient care and reduce healthcare costs, today announced that Troy A. Ignelzi, chief financial officer of scPharmaceuticals, will present at the BMO Capital Markets Prescriptions for Success Healthcare Conference at 4:30 PM ET on Thursday, December...
December 12, 2017 –OXFORD, UK – PsiOxus Therapeutics, Ltd. (PsiOxus) today announced that the Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors, has been approved and, per the licensing agreement between the parties, Bristol-Myers Squibb will make a US $15 million milestone payment to PsiOxus. “This is an exciting development...
With calls for applications for two major thematic grants, the Lundbeck Foundation is ready to provide funding of up to 250 million Danish kroner for brain research. The larger of the two is aimed at personalised medicine, supporting national strategy in this field. Brain disorders cost society more than cancer, diabetes and cardiovascular disease together....
With the help of an ingenious calculation method, a Danish-American research project has identified a further 62 human genes which, “with very high likelihood”, will develop carcinogenic mutations. This method enables identification of the cause of many cases of cancer which, today, end up being classified as ‘inexplicable’. We can learn a lot about a...
“We put the brain first.” This is the title of the Lundbeck Foundation’s new strategy for charitable activities. One of the objectives of the strategy is to elevate Denmark to the ranks of the world’s leading brain research nations, and it is against this background that the Foundation aims to increase its grants to the...
Funds will support Phase 2 study of Reltecimod for Acute Kidney Injury; Phase 3 study of Reltecimod for Necrotizing Soft Tissue Infections (“flesh eating bacteria”) ongoing Ness Ziona, Israel and Chapel Hill, NC – December 4, 2017 – Atox Bio, a clinical stage biotechnology company developing novel therapies for critically ill patients, today announced that it has raised...
1 2 3 9

News

Open for applications for postdoc scholarships
11. July 2019
Shorter hospital stays after hip and knee surgery
8. July 2019
The Lundbeck Foundation is seeking new fellows
8. July 2019

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge